Series A · Healthtech
Dialybrid raises €15m Series A for dialysis-access graft
XGEN Venture led the round, with CDP Venture Capital’s Rilancio Fund participating.
Dialybrid has raised €15 million in Series A financing led by XGEN Venture, alongside CDP Venture Capital’s Rilancio Fund. The capital will support clinical development of its Silkothane graft and preclinical work on other vascular applications.
The company also reported the first implantation in a human study in Italy. The trial is designed to assess safety and performance in 18 adults across four centers.
Use of funds
Clinical development of Silkothane graft
Preclinical research for other vascular applications
Funding history
Series A · This round€15M